Methods for preparation of toxoids from the and type D antigens were measured in Lf using purified toxins of Clostridium botulinum types univalent antitoxins supplied by the Microbiologi-A, B, C, D, and E, and the immunologic re-cal Research Establishment, Porton, England. The Ssponses of animals to univalent aluminum type E antigen in the first toxoid was expressed in phosphate-adsorbed toxoids have been described terms of Lf, but difficulty was encountered with S(1-6). With bivalent type AB toxoid, results of the flocculation of the purified type E toxins, studies in animals (6) and trial in man (7) have and in the last three toxoids the concentrations been presented. The bivalent toxoids were well of type E antigens were expressed in terms of the tolerated and elicited satisfactory responses in LD 50 of the purified toxin before detoxification. man. The percentage of individuals having The purified type C toxin did not flocculate; demonstrable antitoxin titers following the therefore the concentrations of all type C antigens initial series of injections of bivalent toxoid were expressed in terms of LD, 0 equivalents also. depended upon the immunization schedule. The five types of concentrated fluid toxoids and Injections administered at 0, 2 and 10 weeks saline were added to an aluminum phosphate produced the greatest percentage of responses, suspension so that the final product contained and this schedule was selected for routine 1.7 Lf/ml of type A, 0.54 Lf/ml of type B, immunization of man.
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50,000 LD, 0 equivalents of type C, 4 Lf/ml of Formulation of a pentavalent adsorbed type D and 0.5 Lf/ml (ABCDE-1) or 100,000 preparation and study of the immunologic LDso equivalents/ml (ABCDE-6, 7, and 8) of responses of rabbits and guinea pigs to the type E. The final aluminum phosphate concenproduct have been reported by Cardella ef at. tration was 7 mg/mI. A I% thimerosal solution (8). Good responses were obtained to all antigens, was added as a preservative prior to the addition but the responses to the pentavalent toxoid of saline, so that the final concentration was appeared to be slightly less than those obtained 1:10,000. The product was placed oin a mechaniwith univalent control toxoids. The present cal shaker at 370C for 18 to 24 hr and then stored paper presents an extension of these studies to an at 40C. In addition, five univalent control toxoids investigation of the immunologic response of were produced by an identical procedure simulman to the pentavalent preparation. A pre-taneously with pentavalent ABCDE-i toxoid; liminary report has been presented (9) . these univalent toxoids contained identical antigens at the same concentrations as they were tATERIAL5 AND METHODS present in the ABCDE-1 toxoid.
Four pentavalent toxoids suitable for use in Studies of the immunologic response in man to man were prepared by Parke, Davis and Coin-pentavalent toxoids were divided into two parts. pany, Detroit, Michigan, under the dirretion of The initial experiment was carried out with Dr. Henry B. DevUn; these products were toxoid ABCDE-1 and its univalent control designated ABCDE-1, ABCDE-6, ABCDE-7 toxoids and this was followed by an experiment and ABCDE-8. Fluid toxoids of the five types in which the three additional pentavalent toxoids were prepared according to procedures pre-were studied simultaneously. The simultaneous viously described (1-6). Holt's "7/8" aluminum study of toxoids ABCDE-6, ABCDE-7 and phosphate gel (6) was used as an adjuvant in all ABCDE-8 had two objectives. indicated that the final purified toxins of the These titers will be referred to as the lowest mane type were essntially similar with one measurable titers. The procedures for standexception. The type B toxin that, after detoxifica-ardisation of toxins and determination of serum tion, was used in ABCDE-8 contained a similar antitoxin titers were those described previously 11 value but a much lower LD), than the type B (6), except that the gelatin-phosphate buffer toxins used in ABCDE-6 and ABCDE-7. used as a diluent was adjusted to pH 6.5 for all
Individual antigenic response to ea&h antigen types.
were determined by neutralization titrations in Porton type A and type B antitoxins were rice, using the univalent Porton antitoxinh as used as primary standards rather than the primary reference standards. Purified toxins National Institutes of Health antisera because diluted with two parts glycerine and stored at the former were active in flocculation as well a& -20*C were standardized against the reference in neutralization titrations; the change allowed 94 100 100 100 indications that the incidence of mild local reactions was somewhat greater with the penta-* PB, postbooater. valent toxoids than with the bivalent products studied previously (7).
initial injection and 8 weeks after the booster Seventeen persons were immunized with dose are presented in Table I . Antigenic repentavalent ABCDE-1 toxoid, and five or six sponses to all antigens were found 12 weeks after persons per type were immunized with the the initial injection in at least 47% of the inunivalent control toxoids, on a 0-2-10 week dividuals. A considerable drop in titer occurred schedule. Individual titers were determined 12 between 12 and 52 weeks, but with the adand 52 weeks after the initial i-iection; boosters ministration of a booster all titers rose above the were given at 52 weeks, and 0*ers were deter-levels that had been obtained at 12 weeks. Eight mined 8 weeks after the booster nection.
weeks after the booster one individual immunized The data obtained 12 and 5. weeks after the with the pentavalent toxoid did not have a measurable type B titer; all other individuals had were determined for each type on each serum. 1% E 1 The percentages of individuals exhibiting measurable titers following immuniziatio with each of the three pentavalent toxoids am listend mesammbie titers at 52 weeks. A booter given in Table III . Two weeks after completion of the at 52 weeks was very effective, Md all except initial meries a ue proportion of the individuals three of ta titerm were meaaurable 8 weeks after had titers to all types regardless of the toxoid the boostsr. usd. All titers decned between 14 and 52 weeks,
The &,thnm-*, mean and median titer. for all and only a small portion of the individuals had type. ad for each preparation are srown in
IMMUNITY TO TOXINS OF C. BOTULINUM 701 Table IV . In all cases the median titers were antigen; this range ms frequently greater than lesB than the mean titers; the means ranged from 1000-fold. Because of this large variatioi, teets 1.3-to 5.5-fold the median titers. After the initial with lag groups we-ald be r-uim to det"t series, median titers were from 2 to 16 times the even rather substantial differences in antilowest measurable level; after the booster, they genicity resulting from combination of the ranged from 10-to 100-fold the measurable level, antigens. In any event it is evideat that any The results of a rank sum statistical analysis decrease in antigenicity resulting from pentaof the response for each type in the three penta-valent combination is not of a magnitude to valent toxoids are presented in Table V . Signifi-prevent practical use of this combination of cant differences between the products were antigens for immunization of man. observed, and the differences between products
The first human study with pentavalent were more evident after the initial series than toxoid AhCDE-1 was initiated after the product after the booster.
had been held at 40C for 1 year; satisfactory Preliminary consideration was given to the immunization of man was obtained at this time. relationship between the antitoxin titer and A second immunization study 4 months later protection against botulinum intoxication. Since also yielded satisfactory antitoxin titers in man. no such information was available for man, These experiments indicated that the pentaexperiments were carried out in guinea pigs. vaent toxoid produced a good response in man The animals were immunized subcutaneously after it had been held at 4°C for at least 16 with aluminum phosphate-adsorbed univalent months. toxoids and challenged intraperitoneally with
The simultaneous evaluation of toxoids homologous toxin. Immune groups of each type ABCDE-6, ABCDE-7 and ABCDE-8 demonwith mean antitoxin levels of approximately two sav-ted that the laboratory procedures for growth, times the lowest measurable level withstood 10' puri!.atia and detoxification of univalent to 101 mouse intraperitoneal LDs) of homologous botulinum toxins and their incorporation into toxin.
pentavalent toxoids were adaptable to largescale production procedures. All three penta-DISCUSSXON valent preparations elicited satisfactory responses
Procedures for the production of a pentavalent in man and were considered acceptable products. type A, B, C, D and E botulinum toxoid suitable However, statistical analysis of the data showed for use in man have been developed, and four that these products produced significantly products have been tested in mr,. The toxoids different antitoxin responses in man to all types were well tolerated, producing only occasional after the initial series. The antigens in each moderate reactions and no severe reactions in product were standardized on the basis of either man. Each product produced messura anti-Lf or LD&M equivalents; the significant deierence toxin titers to each of the five antigens following in antigenicity between toxoids demonstratux as a three-injection initial series; the percentages of anticipated, that neither L nor L". equivalents measurabletitersrangedfrom23 to10%.A is a precise measure of the antigenicity of the 0.5-ml booster given 52 weeks after the initial botulinum toxois. injection was highly effective, and the percentages Ackfaowed•. The authors hre indebted to of measurable titers following the booster ranged Dr. Alf S. Alving of the Department of Medicize, from 86 to 100%.
Un'versity of Chicago, aM his staff for the Comparison of the respones to the fiveT anti-administration of the toxoids had the collection gens individually with those obtained after of serum sample., L to Dr. George G. Wright administration of the pentaviaent combination for his advice during the preparation of the appeared to indicate that the antigemcity of the toxoid was decreased by combimtion. Statistical msuSript. analvsu, howevr. rft. -. 2e that these apparent differences were not significant in most cases. The difficulty in rt-vling such differences as may 'rifled toxins of CIoxiditsm boteiniw types exist is a result of the Lirge range of titWrp re-A, Z. C, D and E were converted to toxoids and corded within group@ that had received the nime sa*,rbed on aluminum phosphate; four pmreprw 
